Unpack the keys to successful disease control in CRSwNP alongside expert Prof. Vibeke Backer. Learn how to navigate treatment pathways for improved patient quality of life.
The ERS-ISIAN 2025 symposium, featuring Prof. Vibeke Backer and Prof. Sietze Reitsma, titled "Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions," will delve into the complexities of the role of type 2 inflammation in CRSwNP.
Join Drs. Martin Metz, Moshe Ben-Shoshan, and Michelle Tarbox as they share expert insights on the burden of pediatric CSU, as well as key considerations for disease diagnosis and treatment escalation in pediatric and adult patients.
Prof. Peter Hellings and Dr. Stella Lee discuss the concept of remission for patients with chronic rhinosinusitis with nasal polyps.
Join experts Frederik Trinkmann, Monica Kraft, and Arnaud Bourdin on an ADVENT educational symposium, “Distal Airways, Central Role? Clinical Insights Into Type 2 Severe Asthma."
Professors Bouaziz, Paller, and Irvine discuss the clinical burden of atopic dermatitis, the biomarkers of subclinical control, and evidence of potential disease modification in AD at EADV 2025.

In this video from the April 2025 WCPD symposium, Dr Eulàlia Baselga discusses how early intervention during infancy and childhood in patients with AD may reduce the progression of the atopic march. Dr Baselga goes on to review data showing how the reduction of biomarkers such as IgE and CCL17 may reduce inflammation and sensitization that contribute to atopic comorbidities.

This full video presentation of the April 2025 WCPD symposium features Dr Amy Paller, Dr Paula Luna, and Dr Eulàlia Baselga. The faculty present the latest data on the possibility of achieving disease modification in infants and children with atopic dermatitis.
Dr. Nicole Chase describes a potential hypothesis for the link between the shift to an industrialized society and the rise in type 2 inflammatory diseases, highlighting the loss of immunomodulatory mechanisms driven by helminthic infections. She explains how unopposed immune responses to common environmental allergens may cause chronic type 2 inflammation, manifesting throughout the body.
Dr. Lisa Swanson explores a hypothetical scenario of what might have been achievable for adult patients with atopic dermatitis if advanced systemic therapies had been initiated in early childhood, considering the potential impact on atopic progression, mental health, and bone health and growth outcomes.
Join ADVENT faculty members Len Bacharier, Antonella Cianferoni, and Andre Moreira for an educational symposium highlighting type 2 inflammation and its shared and distinct roles in multiple chronic pediatric diseases.
At ATS 2026, the Sanofi & Regeneron ADVENT Booth brings together interactive experiences and educational resources to explore Type 2 inflammation as a key feature underlying both asthma and COPD.